Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) - Trial NCT06305715
Access comprehensive clinical trial information for NCT06305715 through Pure Global AI's free database. This Phase 2 trial is sponsored by Medical College of Wisconsin and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 34 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Medical College of Wisconsin
Timeline & Enrollment
Phase 2
Jul 15, 2024
Jun 15, 2028
Primary Outcome
Progression Free Survival
Summary
This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the
 use of definitive radiation to the primary lung lesion prolongs progression-free survival
 (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC)
 patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06305715
Device Trial